A Pilot Study of Nemolizumab Injections to Treat Lichen Planopilaris A Condition Causing Scalp Hair Loss and Itching Phase 4, Open-Label Treatment Study

What this Trial Is About

Lichen planopilaris LPP is a type of scarring hair loss caused by inflammation, leading to permanent hair loss and uncomfortable scalp symptoms like itching and burning. Current treatments often dont work well and can have side effects, so new targeted options are needed. Nemolizumab, a drug that blocks the IL-31 receptor and is approved for other itchy skin conditions, is being studied as a potential treatment for LPP in this phase 4 pilot study. Participants in the study will receive nemolizumab through subcutaneous injections every 4 weeks, with doses adjusted based on weight. This is a noncontrolled study, meaning all participants receive nemolizumab without comparison to a placebo or other treatment. The study will last at least 24 weeks, during which participants will be monitored for changes in their LPP symptoms. During the study, participants will have their hair loss and scalp condition assessed using specific scoring systems, including the Lichen Planopilaris Activity Index and the Investigator Global Assessment for scarring alopecia. They will also report on scalp itching using a numerical rating scale. Optional scalp biopsies may be performed for research. Safety and treatment effects will be followed over the 24-week period, with all assessments designed to understand how nemolizumab influences LPP activity and symptoms.

Nemolizumab to Treat Lichen Planopilaris, a Noncontrolled, Prospective, Pilot Study.